Status:

COMPLETED

Exercise-induced Cardiac Adaptions in Rheumatoid Arthritis Patients During IL-6 vs. TNF Antibody Therapy

Lead Sponsor:

Rigshospitalet, Denmark

Conditions:

Rheumatoid Arthritis

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

The present study will investigative the physiological effects of the cytokines interleukin-6 (IL-6) and tumor necrosis factor (TNF) on the adaptive changes to exercise in patients with rheumatoid art...

Detailed Description

80 patients with rheumatoid arthritis who are being treated with either interleukin-6 receptor blockers (IL-6Rb) or tumor necrosis factor inhibitors (TNFi) for a minimum of four months prior to enroll...

Eligibility Criteria

Inclusion

  • Age \>= 18 and \<70 years
  • Informed consent
  • Diagnosed RA based on the 2010 American College of Rheumatology/ EULAR criteria. In biological treatment with either IL-6rB og TNFi over four months prior to enrollment
  • Low RA disease activity, based on the Disease Activity Score-28 ESR for Rheumatoid Arthritis (DAS28) \<=3.2
  • An electrocardiogram without features of left ventricular hypertrophy defined by the European Society of Cardiology
  • Females of childbearing potential have to use one or more of the following highly effective methods for contraception in order to be included:
  • Vasectomized partner
  • Bilateral tubal occlusion
  • Sexual abstinence
  • Intrauterine device
  • Hormonal contraception
  • Females who are considered to have no childbearing potential are
  • Bilateral tubal ligation
  • Bilateral oophorectomy
  • Complete hysterectomy
  • Postmenopausal defined as 12 months with no menses without an alternative medical cause

Exclusion

  • Health conditions that prevent participating in the exercise intervention determined by the Project Coordinator
  • Subjects who cannot undergo MRI scans (metallic implants or claustrophobia)
  • Corticosteroid use per os \> 10 mg/day within seven days of study enrollment
  • Intramuscular corticosteroid within 3 weeks of the study enrollment
  • Grade 2 hypertension (systolic BP \> 160 mmHg and/or diastolic BP \>100 mmHg) despite the use of antihypertensive drugs.
  • Pregnancy
  • Subjects with insulin dependent Diabetes

Key Trial Info

Start Date :

January 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2023

Estimated Enrollment :

69 Patients enrolled

Trial Details

Trial ID

NCT05215509

Start Date

January 1 2021

End Date

December 31 2023

Last Update

February 2 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Rigshospitalet

Copenhagen, Denmark, 2100